AN2 Therapeutics, Inc. (ANTX) Stock Ticker
Market factors today
Unlock the full ANTX picture
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
ANTX stock facts
| Ticker symbol | ANTX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $175.8M |
| CEO | Eric E. Easom |
| Employees | 21 |
| Headquarters | Menlo Park, CA, US |
| IPO date | 2022-03-25 |
| Website | www.an2therapeutics.com |
What you can see for ANTX on Tickr
Live ANTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ANTX report.
Rankings
FAQ
What is the ticker symbol for AN2 Therapeutics, Inc.?
The ticker symbol for AN2 Therapeutics, Inc. is ANTX, listed on the NASDAQ Global Select.
What is ANTX?
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.…